References
- Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr. 2013;163(1):213–216
- Johnston L, O’Malley P, Bachman J, Schulenberg J. Key findings on adolescent drug abuse. 2012. Available at: http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2012.pdf (accessed 2015)
- Kraft A. Big increase in deaths, poisonings from synthetic marijuana. CBS News. [http://www.cbsnews.com/news/deaths-poisonings-from-synthetic-marijuana-spice-k2/. (published June 11 2015; accessed September 23 2015)
- Mayor De Blasio announces multi-agency strategy to end sale and use of K2, linked to recent spike in emergency room visits. States News Service [http://www1.nyc.gov/office-of-the-mayor/news/625-15/mayor-de-blasio-multi-agency-strategy-end-sale-use-k2-linked-recent-spike (published September 17 2015; accessed 2015)]
- Crews B. The challenges of testing designer drugs. Am Assoc Clin Chem. 2013. Available at https://www.aacc.org/publications/cln/articles/2013/february/cannabinoids (accessed 2015)
- Hess C, Stockhausen S, Kernbach-Wighton G, Madea B. Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Sci Int. 2015;257:e6–e11
- Davis C, Boddington D. Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ. 2015;24(10):e162–e163
- Shanks KG, Winston D, Heidingsfelder J, Behonick G. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int. 2015;252:e6–e9
- Tse R, Kodur S, Squires B, Collins N. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J. 2014;44(9):934–936
- Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988;145(8):976–981
- Manchikanti L, Cash KA, Damron KS, et al. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006;9(3):215–225
- Howard J, Anie KA, Holdcroft A, et al. Cannabis use in sickle cell disease: A questionnaire study. Br J Haematol. 2005;131(1):123–128
- Boulmay B, Lottenberg R. Cocaine abuse complicating acute painful episodes in sickle cell disease. South Med J. 2009;102(1):87–88
- Steen RG, Fineberg-Buchner C, Hankins G, et al. Cognitive deficits in children with sickle cell disease. J Child Neurol. 2005;20(2):102–107
- Atkin K, Ahmad WI. Living a ‘normal’ life: Young people coping with thalassaemia major or sickle cell disorder. Soc Sci Med. 2001;53(5):615–626
- Bakare MO. Case report: Psychosis in an adolescent with sickle cell disease. Child Adolesc Psychiatry Ment Health. 2007;1:6. doi: 10.1186/1753-2000-1-6
- Spiegel DR, Messerschmidt C, Morewitz J, Akintola M. A case of recurrent psychosis during sickle cell disease crisis treated successfully with ziprasidone. Clin Schizophr Relat Psychoses. 2003;6(4):197–201
- The Management of Sickle Cell Disease, 4th Ed. http://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf. National Institutes of Heath (NIH) Publication No. 02-2117, 2002 (accessed September 21 2015)
- Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: Perceptions of medical practitioners. J Pain Symptom Manage. 1997;14(3):168–174